

# Nottingham University Hospital NHS Trust Lung Cancer Pathway Development Project (PDP)



This project was done in collaboration with MSD and Nottingham University Hospital NHS Trust

July - November 2022



## WHAT IS A PDP?

The Pathway Development Programme (PDP) is a collaborative working agreement between MSD and the NHS designed to support healthcare providers to optimise cancer pathways, enabling patients to be diagnosed and treated faster.



## Objectives



To enhance the efficiency, quality, productivity, and overall experience of the lung cancer service at Nottingham University Hospitals.

The desired result was the implementation of an improved lung cancer pathway, in line with the national optimal lung cancer pathway, and the achievement of key targets such as the lung cancer 28-day Faster Diagnostic Standard, the 31-day treatment target, and the 62-day referral to treatment Cancer Waiting Time (CWT) Targets.

## Challenges



Lung cancer diagnostic pathways can be complicated and adherence to the 62-day pathway is challenging. Faster treatment and diagnosis improves outcomes, reducing the risk of performance status decline and potentially enabling patients to have access to a broader range of treatment options.

## Solution



Through the collaboration between MSD and Nottingham University Hospitals, a solution was developed to enhance the lung cancer service through:

- Pathway mapping of the lung cancer service in Nottingham University Hospital NHS Trust and creation of Lucid charts depicting the current pathway
- Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs
- Implementation of an optimised lung cancer pathway for each site managing lung cancer patients across Nottingham

## Impact



- Quicker diagnosis and time to treatment of lung cancer has been reported, potentially improving patient outcomes
- Patients now have access to Nottingham Education Materials for smoking cessation, diet, exercise, and psychological support, which was not previously available, likely improving patient experience.

Overall improvement of the lung cancer pathway targets

28-day Faster Diagnostic Standard improvement of **6.9%**

2WW improvement of **4.7%**  
(100% in Feb 2023)

31-day treatment target improvement of **1.5%**

\*The 62-day referral CWT target is an ongoing measurement as only data to Feb 2023 was available at the time of the outcome summary publication. NUH are continuing to monitor the impact of the project and CWT data.